All In Biotech

NDA 210795 · Glaxosmithkline

Krintafel

Tafenoquine Succinate · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jul 20, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

39

7 Phase 3, 8 recruiting

FAERS reports

11

7 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 2, 2023.

KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection [see Dosage and Administration ( 2.2 )] . Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. • Concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria [see Warnings and Precautions ( 5.6 )] . KRINTAFEL is an antimalarial indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection. ( 1 ) Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. ( 1 ) • The concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria. ( 1 , 5.6 )

Mechanism: Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 20, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • KRINTAFEL · TAFENOQUINE SUCCINATE EQ 150MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tafenoquine" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3
  • off label use3
  • bacteraemia2
  • blood fibrinogen decreased2
  • blood lactate dehydrogenase increased2
  • blood triglycerides increased2
  • candida infection2
  • drug effective for unapproved indication2
  • haemolysis2
  • haemolytic anaemia2
  • haemophagocytic lymphohistiocytosis2
  • infection2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20192
20201
20224
20232
20241
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.